Virale hämorrhagische Fieber (VHF) mit Potenzial einer Mensch-zu-Mensch-Übertragung

Stefan Schmiedel; Timo Wolf

doi:10.1055/a-2241-4173

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2025; 150(13): a22414173
DOI: 10.1055/a-2241-4173

CME-Fortbildung

Virale hämorrhagische Fieber (VHF) mit Potenzial einer Mensch-zu-Mensch-Übertragung

Viral Hemorrhagic Fever (VHF) with a Potential for Human-to-Human Transmission

Authors

Stefan Schmiedel
Timo Wolf

Abstract

Virale hämorrhagische Fieber (VHF) werden u.a. durch das Lassa-Virus, Ebola-Virus, Marburg-Virus und das Krim-Kongo-Virus verursacht. Dort, wo diese Viren endemisch vorkommen, verursachen sie sowohl zoonotische Einzelerkrankungen als auch epidemische Ausbrüche mit Mensch-zu-Mensch-Übertragungen und teils hoher Letalität. Letztere zählen zu den „high-consequence infectious diseases“ (HCID) und sollen hier näher betrachtet werden.

Abstract

Lassa virus, Ebola virus, Marburg virus and Crimean Congo virus, as well as much rarer viruses that cause Viral Hemorrhagic Fevers (VHF), are zoonoses. Where these viruses are endemic, they cause both individual diseases, so-called “spill-over events” with isolated human cases after transmission from their animal reservoir, as well as epidemic outbreaks with cases of disease transmitted from person to person, and often high mortality. In this article, the focus will be on VHFs with the potential for human-to-human transmission; these diseases are so-called “high-consequence infectious diseases (HCID)” with partly considerable potential for epidemic spread and the risk of nosocomial disease transmission. In some cases, other viral infections without the possibility of human-to-human transmission, such as yellow fever or dengue fever, can also be accompanied by bleeding or multi-organ failure.

Schlüsselwörter

virales hämorrhagisches Fieber - Lassa-Fieber - Ebola-Virus-Erkrankung - Marburg-Virus-Erkrankung - Krim-Kongo-Hämorrhagisches Fieber - Erkrankungen durch hochpathogene Erreger

Keywords

Viral hemorrhagic fever - Lassa-fever - Ebola-virus disease - EVD - Marburg-virus disease - MVD - Krim-Kongo-hemorrhagic fever - high-consequence-infectious diseases - HCID

Bibliographical Record
Stefan Schmiedel, Timo Wolf. Virale hämorrhagische Fieber (VHF) mit Potenzial einer Mensch-zu-Mensch-Übertragung. Dtsch Med Wochenschr 2025; 150: a22414173.
DOI: 10.1055/a-2241-4173

Full Text

References

Literatur
1 Robert Koch Institut. Arbeitskreis STAKOB. Accessed April 10, 2025 at: www.stakob.de
2 Factsheet ECDC. Ebola- und Marburgfieber. 2019 Accessed April 10, 2025 at: www.ecdc.europa.eu/en/ebola-and-marburg-fevers/facts/factsheet
3 Robert Koch Institut (RKI). STAKOB-Stellungnahme zur sexuellen Transmission von Ebolafieber. 2016 Accessed March 18, 2025 at: www.rki.de/ebolafieber
4 Kreuels B, Wichmann D, Emmerich P. et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014; 371 (25) 2394-2401
5 Mulangu S, Dodd LE, Davey RT. et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med 2019; 381: 2293-2303
6 Markham A. REGN-EB3: First Approval. Drugs 2021; 81: 175-178
7 Lee A. Ansuvimab: First Approval. Drugs 2021; 81: 595-598
8 MSD Fachinformation Ervebo. 2020 Accessed April 10, 2025 at: www.msd.de/wp-content/uploads/sites/33/2021/09/GI_ervebo_injektionsloesung_1ml.pdf
9 EMA Ervebo. 2021 Accessed April 10, 2025 at: www.ema.europa.eu/en/documents/procedural-steps-after/ervebo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
10 EMA First Ebola Vaccine. 2019 Accessed April 10, 2025 at: www.ema.europa.eu/en/news/new-vaccine-prevention-ebola-virus-disease-recommended-approval-european-union
11 Gsell PS, Camacho A, Kucharski AJ. et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infect Dis 2017; 17: 1276–1284. .
12 EMA Zabdeno EPAR Anhang I. Accessed April 10, 2025 at: www.ema.europa.eu/en/medicines/human/EPAR/zabdeno
13 Pollard AJ, Launay O, Lelievre JD. et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2021; 21: 493-506
14 EMA Mvabea EPAR Produkt-Info. 2020
15 Badio M, Lhomme E, Kieh M. et al. Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. Trials 2021; 22: 86
16 Stille W, Böhle E, Helm E. et al. Über eine durch Cercopithecus aethiopicus übertragenen Infektionskrankheit. Dtsch Med Wochenschr 1968; 93: 572-582
17 Centers for Disease Control and Prevention (CDC). History of Marburg Outbreaks. Accessed February 28, 2023 at: www.cdc.gov/vhf/marburg/outbreaks/chronology.html
18 Pigott DM, Golding N, Mylne A. et al. Mapping the zoonotic niche of Marburg virus disease in Africa. Trans R Soc Trop Med Hyg 2015; 109: 366-378
19 ProMED. Mail Alerts. Accessed March 14, 2023 at: https://promedmail.org/promed-post?place=8708654,68892
20 Martini GA, Müller G. Marburg-Virus: Entdeckung eines bis dahin unbekannten Erregertyps. Deutsch Ärzteblatt 2008; 105 (04) A-147/B
21 Ajelli M, Merler S. Transmission potential and design of adequate control measures for Marburg hemorrhagic fever. PLoS One 2012; 7e: 50948
22 Schneider KA, Bonney JHK, Kubio C. et al. Reconsidering the incubation periof of Marburg Virus Disease. Lancet 2022; 22: 1525-1526
23 Radohitzky SR, Iversen P, Lu X. et al. Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro. Sci Rep 2023; 13: 3131
24 Cross RW, Bornholdt ZA, Prasad AN. et al. Combination therapy protects macaques against advanced Marburg virus disease. Nat Commun 2021; 12: 1891
25 de La Vega MA, Xiii A, Massey S. et al. An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses. Expert Opin Drug Discov 2024; 19: 1185-1211
26 Rigby I, Michelen M, Dagens A. et al. Standard of care for viral haemorrhagic fevers (VHFs): a systematic review of clinical management guidelines for high-priority VHFs. Lancet Inf Dis 2023; 23: e240-e252
27 Hoogstraal H. The epidemiology of tick borne Crimean-Congo hemorrhagic fever in Asia, Europe and Africa. J Med Entomol 1979; 15: 307-417
28 Simpson DI, Knight EM, Courtois G. et al. Congo virus: A hitherto undescribed virus occurring in Africa. I. Human isolations-clinical notes. East Afr Med J 1967; 44: 86-92
29 Ergönül Ö. Crimean-Congo haemorrhagic fever. Lancet Inf Dis 2006; 6: 203-214
30 Chinikar S, Shayesteh M, Khakifirouz S. et al. Nosocomial infection of Crimean–Congo haemorrhagic fever in eastern Iran: Case report. Travel Med Infect Dis 2013; 11: 252-255
31 Negredo A, De la Calle-Prieto F, Palencia-Herrejón E. et al. Autochthonous Crimean-Congo Hemorrahgic Fever in Spain. N Engl J Med 2017; 377: 154-161
32 Ergönül O, Battal I. Potential sexual transmission of Crimean-Congo hemorrhagic fever infection. Infect Dis 2014; 67 (02) 137-138
33 Ergonul O, Akgunduz S, Kocaman I. et al. Changes in temperature and the Crimean Congo hemorrhagic fever outbrea in Turkey. Clin Microbiol Infect 2005; 11: 360
34 Grandi G, Chitimia-Dobler L, Choklikitumnuey P. et al. First records of adult Hyalomma marginatum and H. rufipes ticks (Acari: Ixodidae) in Sweden. Ticks Tick Borne Dis 2020; 11: 101403
35 Monsalve L. Emerging and vector-borne zoonotic diseases. ECCMID. 2021
36 Juanes HLJ, Carbonell C, Sendra BF. et al. Crimean-Congo Hemorrhagic Fever, Spain, 2013–2021. Emerg Infect Dis 2023; 29: 252-259
37 Promedmail. Archive Number 20240828.8718394. Accessed August 28, 2024 at: www.promedmail.org
38 Hawman DW, Felann H. Crimean–Congo haemorrhagic fever virus. Nat Rev Microbiol 2023; 21: 463-477
39 Akıncı E, Bodur H, Leblebicioglu H. Pathogenesis of Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2013; 13 (07) 429-437
40 Swanepoel R, Gill DE, Shepherd AJ. et al. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989; 11: 794-800
41 van Eeden PJ, van Eeden SF, Joubert JR. et al. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part II. Management of patients. S Afr Med J 1985; 68: 718-721
42 Coutard B, Gorbalenya AE, Snijder EJ. et al. The VIZIER project: preparedness against pathogenic RNA viruses. Antiviral Res 2008; 78: 37-46
43 World Health Organization (WHO). Crimean-Congo haemorrhagic feverWHO. Accessed March 11, 2024 at: www.who.int/news-room/fact-sheets/detail/crimean-congo-haemorrhagic-fever
44 Hawman DW, Haddock E, Meade-White K. et al. Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Antiviral Res 2018; 157: 18-26
45 Vassilenko SM, Vassilev TL, Bozadjiev LG. et al. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet 1990; 335: 791-792
46 Ergonul O, Celikbas A, Baykam N. et al. Analysis of the mortality among the patients with Crimean Congo hemorrhagic fever virus infection. Clin Microbiol Infect 2006; 12: 551-554
47 Robert Koch Institut. Ebolafieber.
48 FDA Approval Ridgeback. 2020 Accessed April 10, 2025 at: www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761172Orig1s000RiskR.pdf